Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07249554 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy for Alcohol Use Disorder
A Phase 2 study, sponsored by Johns Hopkins University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT07249554: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT07249554 is a Phase 2 study that has not yet begun recruiting, run by Johns Hopkins University. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07249554, a Phase 2 study, has not yet begun recruiting, sponsored by Johns Hopkins University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.
Primary Outcome
Participant-reported adverse events during the course of the trial
Interventions
- DRUG Placebo
- DRUG Naltrexone (oral tablets)
- DRUG Glucagon-Like Peptide-1 Agonist (GLP-1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
What is known before NCT07249554 opens enrollment
NCT07249554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07249554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07249554 about?
NCT07249554 is a clinical study titled "Combination Therapy for Alcohol Use Disorder". This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.
What is the current status of trial NCT07249554?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2026-07. Estimated completion is 2028-09.
What interventions are being tested in trial NCT07249554?
The interventions under investigation include: Placebo (DRUG), Naltrexone (oral tablets) (DRUG), Glucagon-Like Peptide-1 Agonist (GLP-1) (DRUG).
Who is sponsoring clinical trial NCT07249554?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07249554's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia